| Revenue growth | FY26 revenue ₹270.17 Cr, down 7.7% YoY. |
|---|---|
| Margins | Gross margin improved 80 bps to 44.2% on better mix. |
| Order book | 964 total registered products; 200+ in pipeline. |
| Demand visibility | Strong growth in LATAM; 49 new product registrations secured. |
| Management confidence | High on backward integration and LATAM market diversification. |
Growth
FY26 Consolidated Revenue down 7.7% YoY; PAT fell 94.3% to ₹1.42 Cr; LATAM revenue grew 11% YoY.
Outlook
Received manufacturing license for Hyderabad facility; targeting WHO-GMP certification and deeper penetration in Latin America and Africa.
Risks
Extended working capital cycles in institutional business, particularly in Angola; exit from ancillary Building Hardware business.
Earnings Call filed with NSE, NSE: BALAXI. Summary written with AI assistance from the document.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹22.82
- Market cap
- ₹126.0 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 52.0×Sector 50.4×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Balaxi Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.3 Cr, Up 333.3% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹80.7 Cr (+14.1% YoY) and net profit of ₹1.3 Cr (+333.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.3 Cr · +333.3% YoY
Balaxi Pharmaceuticals Q4 FY26 Results: Net Profit ₹0.6 Cr, Down 93.0% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹70.7 Cr (-7.3% YoY) and net profit of ₹0.6 Cr (-93.0% YoY) for Q4 FY26.
- Key figure
- Net profit ₹0.6 Cr · -93.0% YoY